Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study by M. Ravizza et al.
Atazanavir and darunavir in pregnant women with HIV: evaluation of
laboratory and clinical outcomes from an observational national study
M. Floridia1*, G. Masuelli2, M. Ravizza3, B. Tassis4, I. Cetin5, M. Sansone6, A. Degli Antoni7, G. Simonazzi8,
A. Maccabruni9, D. Francisci10, V. Frisina2, G. Liuzzi11, S. Dalzero3 and E. Tamburrini12 on behalf of The Italian
Group on Surveillance of Antiretroviral Treatment in Pregnancy†
1National Centre for Global Health, Istituto Superiore di Sanita`, Rome, Italy; 2Department of Obstetrics and Neonatology, Citta` della
Salute e della Scienza Hospital and University of Turin, Turin, Italy; 3Department of Obstetrics and Gynaecology, DMSD San Paolo
Hospital Medical School, University of Milan, Milan, Italy; 4Obstetric and Gynaecology Unit, Fondazione IRCCS Ospedale Maggiore
Policlinico di Milano, Milan, Italy; 5Department of Obstetrics and Gynaecology, Luigi Sacco Hospital and University of Milan, Milan, Italy;
6Department of Neurosciences, Reproductive and Dentistry Science, University Federico II, Naples, Italy; 7Department of Infectious
Diseases and Hepatology, Azienda Ospedaliera di Parma, Parma, Italy; 8Department of Medical and Surgical Sciences, Policlinico
Sant’Orsola-Malpighi and University of Bologna, Bologna, Italy; 9IRCCS S. Matteo and Department of Internal Medicine, University of
Pavia, Pavia, Italy; 10Clinic of Infectious Diseases, Azienda Ospedaliera ’Santa Maria’, Terni and University of Perugia, Perugia, Italy;
11I.N.M.I. Lazzaro Spallanzani, Rome, Italy; 12Department of Infectious Diseases, Catholic University, Rome, Italy
*Corresponding author. Tel: 39-06-4990-3228; Fax: 39-06-4938-7199; E-mail: marco.floridia@iss.it
†Members are listed in the Acknowledgements section.
Received 5 September 2017; returned 13 October 2017; revised 17 November 2017; accepted 18 November 2017
Background: Atazanavir and darunavir represent the main HIV PIs recommended in pregnancy, but comparative
data in pregnant women are limited. We assessed the safety and activity profile of these two drugs in pregnancy
using data from a national observational study.
Methods: Women with atazanavir or darunavir exposure in pregnancy were evaluated for laboratory measures
and main pregnancy outcomes (e.g. preterm delivery, low birthweight, non-elective caesarean section and neo-
natal gestational age-adjusted birthweight Z-score).
Results: Final analysis included 500 pregnancies with either atazanavir (n"409) or darunavir (n"91) exposure.
No differences in pregnancy outcomes, weight gain in pregnancy, drug discontinuations, undetectable HIV-RNA,
haemoglobin, ALT, total cholesterol, HDL cholesterol and LDL cholesterol were observed between the two
groups. At third trimester, exposure to darunavir was associated with higher levels of plasma triglycerides
(median 235.5 versus 179 mg/dL; P"0.032) and a higher total cholesterol/HDL cholesterol ratio (median 4.03
versus 3.27; P"0.028) and exposure to atazanavir was associated with higher levels of plasma bilirubin (1.54
versus 0.32 mg/dL; P,0.001).
Conclusions: In this observational study, the two main HIV PIs currently recommended by perinatal guidelines
showed similar safety and activity in pregnancy, with no evidence of differences between the two drugs in terms
of main pregnancy outcomes. Based on the minor differences observed in laboratory measures, prescribing
physicians might prefer either drug in some particular situations where the different impacts of treatment on
lipid profile and bilirubin may have clinical relevance.
Introduction
Current guidelines for HIV treatment usually recommend atazana-
vir and darunavir (with low-dose ritonavir) as preferred HIV PIs in
pregnant women.1,2 There is, however, limited comparative infor-
mation for these two drugs with respect to metabolic profile in
pregnancy, effective viral suppression before delivery and, in gen-
eral, pregnancy and infant outcomes. In order to further explore
this issue, we analysed a national cohort of pregnant women with
HIV, comparing in women with gestational exposure to atazanavir
or darunavir some laboratory parameters, such as plasma lipid
profile, HIV viral load, liver function tests and haemoglobin, and
some maternal and infant outcomes, such as preterm delivery,
low birthweight, non-elective caesarean section and birthweight
Z-score.
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please email: journals.permissions@oup.com.
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Patients and methods
Data from the Italian National Programme on Surveillance of Antiretroviral
Treatment in Pregnancy were used. This is a national observational study
of pregnant women with HIV established in Italy in 2001. The women
and infants are followed during routine clinical care and treatments are
decided by the treating physician, usually according to existing guidelines.
Laboratory and clinical data are collected from hospital records of obstet-
rics, infectious diseases and paediatrics departments, following the wom-
en’s consent, using a patient information sheet that has received approval
by the competent Ethics Committee (National Institute for Infectious
Diseases L. Spallanzani, Rome). Gestational age is determined on the basis
of the last menstrual period, ultrasound biometry or both. Preterm and very
preterm delivery are defined as delivery before 37 and 32 completed weeks
of gestation, respectively, and low and very low birthweight by values below
2500 and 1500 g, respectively. Caesarean section is considered elective if
performed before the rupture of membranes and the onset of labour and
non-elective if performed after the rupture of membranes or onset of
labour or both.
All the results reported here are based on data extracted from the gen-
eral database on 20 June 2017 and refer to pregnancies that occurred since
May 2004 (date of first reported exposure to atazanavir). The main out-
comes evaluated were non-elective caesarean section, preterm and very
preterm delivery, low and very low birthweight and gender- and gestational
age-adjusted percentiles for birthweight (calculated according to national
reference standards).3 Other outcomes included HIV transmission, infant
mortality and birth defects, defined according to the Antiretroviral
Pregnancy Registry definition.4 In women exposed to atazanavir or daruna-
vir in pregnancy without discontinuation the following laboratory parame-
ters were also compared: ALT, bilirubin, haemoglobin, triglycerides, total
cholesterol, HDL cholesterol, LDL cholesterol and total cholesterol/HDL cho-
lesterol ratio. Recommended drug dosages followed existing guidelines.
Laboratory indexes were summarized as medians with IQRs and com-
pared using the Mann–Whitney U-test. Qualitative variables were com-
pared using the v2 or Fisher’s test. P values ,0.05 were considered
statistically significant. All analyses were performed using SPSS software,
version 22 (IBM Corp, 2013, Armonk, NY, USA).
Ethics approval
Ethics approval was obtained from the Ethics Committee of the I.N.M.I.
Lazzaro Spallanzani in Rome (ref. deliberation 578/2001, 28 September
2001).
Results
First exposure to atazanavir in pregnancy was reported in 2004
and first exposure to darunavir in 2007. Between May 2004 and
June 2017, 3045 pregnancies were reported. Following exclusion
of 140 recent pregnancies (4.6%) with possible reporting delay
(outcome not reported within 18 months from expected date of
delivery) and of 790 cases (25.9%) with missing outcome informa-
tion.18 months from expected date of delivery, 2115 pregnancies
(69.5%) with available information on pregnancy outcome were
considered. Among the cases excluded, 580 had no information at
all except for date of last menstrual period and age (the basic clini-
cal information required for the initial report of the pregnancy). The
remaining 350 excluded cases had some information available
and were compared with the 2115 cases considered for subse-
quent analyses (Table 1, left side). For some laboratory variables,
only a limited proportion of the 350 excluded cases had available
information, because missing outcome was also associated with
missing laboratory data at the start of pregnancy. No differences
were found between the two groups for age, CD4 count, plasma
HIV viral load, months since HIV diagnosis, total bilirubin, plasma
triglycerides, total cholesterol, total cholesterol/HDL cholesterol
ratio and ALT. The two groups were also similar for nationality, his-
tory of drug use, HCV seropositivity, diagnosis of HIV in pregnancy,
history of hypertension, nephropathy and diabetes, and parity.
Excluded women were more commonly on ART at conception and
HBV positive (Table 1, left side). Among the 350 cases excluded,
66 had exposure to atazanavir, 22 to darunavir and 2 to both drugs.
Among the 2115 cases with known outcome, 409 (19.3%) had
exposure to atazanavir during pregnancy, 91 (4.3%) to darunavir
and 8 (0.4%) to both (sequentially). Cases sequentially exposed to
both drugs were excluded from all comparisons, leaving 500
evaluable cases. Following the first exposure reported, the propor-
tion of exposed pregnancies increased significantly over time for
both drugs (P,0.001, v2 for trend), with a peak in 2013 for ataza-
navir (62/173, 35.8% of all pregnancies) and in 2014 for darunavir
(27/143, 18.9%). Among cases exposed in pregnancy to either
drug, 315 (63.0%) were on treatment at the start of pregnancy,
with no differences between groups (atazanavir: 255/409, 62.3%;
darunavir: 60/91, 65.9%; P"0.522, v2 test). Only a small fraction
of such cases had a subsequent discontinuation (39/315, 12.4%),
with no significant differences between groups (atazanavir:
34/255, 13.3%; darunavir: 5/60, 8.3%; P"0.290, v2 test). In most
of these discontinuations, atazanavir or darunavir was replaced by
other drugs for treatment optimization, in the absence of toxicity
or treatment inefficacy (data not shown).
The comparison of baseline characteristics (epidemiology, HIV
infection and laboratory data) for the two treatment groups is
shown in Table 1 (right side). At the start of pregnancy, women on
atazanavir were older, had a shorter interval since HIV diagnosis,
slightly higher median plasma HIV-RNA levels and significantly
higher plasma total bilirubin levels. No other significant differences
were found in laboratory measures or in demographic and clinical
characteristics (Table 1, right side).
The comparison of the main laboratory indexes, performed in
women with continued exposure in pregnancy to either drug with-
out discontinuation, showed some significant differences between
the two groups (Table 2). Treatment with darunavir was associ-
ated with higher levels of plasma triglycerides (significant at third
trimester) and higher values of the total cholesterol/HDL choles-
terol ratio (significant at both first and third trimesters), while
treatment with atazanavir was associated with higher levels of
plasma bilirubin (significant at both trimesters). No differences
were observed at either trimester in levels of haemoglobin, ALT,
total cholesterol, HDL cholesterol and LDL cholesterol, and in
changes observed between first and third trimesters for all the
above parameters (all P values0.15; Table 2).
The main pregnancy outcomes for the two groups are summar-
ized in Table 3. No significant differences were observed between
the two groups, with similar rates of preterm and very preterm
delivery, low and very low birthweight, pregnancies not ending in a
live birth, emergency caesarean delivery, complications of delivery,
neonatal death and birth defects. The two groups were also similar
for increase in body weight in pregnancy (median 11 kg in both
groups; IQR 8–14 for atazanavir, 7.5–13 for darunavir; P"0.669)
and for rates of urinary infections, vaginal infections, hypertension,
glucose metabolism abnormalities and anaemia (data not
shown). Among 353 infants with HIV status available, only one
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case of HIV transmission (0.3%) was observed (in the atazanavir
group). Among the five neonatal deaths reported, three were in
severely preterm infants (,30 weeks), likely caused by complica-
tions related to prematurity, one was due to respiratory failure in
an infant with congenital defects and the other occurred in a term
infant with neonatal streptococcal sepsis.
Discussion
Current guidelines for pregnant women with HIV usually recom-
mend atazanavir or darunavir (both with low-dose ritonavir) as the
preferred PIs for use in pregnancy.1,2 The present analysis, based
on 500 pregnancies exposed, provides new comparative informa-
tion. The proportion of evaluable cases reflects the earlier introduc-
tion and more common use of atazanavir compared with
darunavir. Reassuringly, all the main pregnancy and infant out-
comes were equally frequent in the two groups and the rate of HIV
transmission was minimal, with only one case reported.
Although this case series is to our knowledge the largest com-
paring these two drugs in pregnant women, caution is necessary in
the interpretation of outcome data for several reasons. The num-
ber of events, particularly for some infrequent outcomes (such as
very preterm delivery and very low birthweight), was small and the
absence of significant differences should be considered within the
context of the statistical power of the study, which can be
adequate to detect only large differences between groups. Overall,
the rates of all main events were similar to those of the
entire study population of pregnant women with HIV, as shown in
Table 3, but for some outcomes the numbers show some variabil-
ity between groups that should be explored in larger studies, possi-
bly pooling data from multiple cohorts.
In terms of laboratory outcomes, the two drugs were equally
effective in producing an undetectable viral load at the end of preg-
nancy, indicating comparable virological efficacy in pregnancy,
with even higher rates of viral suppression compared with the
entire study population (Table 3). Some differences were observed
in some laboratory indexes: atazanavir was clearly associated with
higher levels of bilirubin, but with no higher rates of drug discontin-
uation or adverse outcomes, in line with other observations that
indicate that the clinical impact of this drug effect in both mothers
and infants is generally limited.5–7 Apart from bilirubinaemia, the
only other significant differences observed between the two drugs
in laboratory parameters involved a slightly better metabolic pro-
file with atazanavir. This drug has shown a favourable lipid profile
in clinical trials8,9 and in pregnancy10 compared with lopinavir, but
there are less consistent findings regarding the comparison with
darunavir in terms of lipid profile.11–15 The present study indicates
in pregnant women a better lipid profile with atazanavir compared
with darunavir, with lower triglyceride levels (contrary to some
studies in the general population that showed an opposite
effect)12,13 and a lower total cholesterol/HDL cholesterol ratio
(consistent with Martinez et al.,11 2014). Although pregnancy may
Table 1. Baseline characteristics of the population studied according to outcome status (left side) and to exposure in pregnancy to the two drugs
studied (right side)
350 with outcome
unknown
2115 with outcome
known Pa
409 with outcome
known, atazanavir
91 with outcome
known, darunavir Pa
n median (IQR) n median (IQR) n median (IQR) n median (IQR)
Age (years) 343 32 (27–37) 2096 33 (29–36) 0.233 409 34 (30–38) 91 32 (27–37) 0.012
CD4 count (cells/mm3) 208 547 (404–696) 931 512 (360–710) 0.509 195 560 (389–752) 51 560 (361–725) 0.543
HIV-RNA (log copies/mL) 177 1.70 (1.60–3.35) 869 1.70 (1.60–3.04) 0.872 278 1.70 (1.57–3.48) 60 1.60 (1.57–2.15) 0.025
Months since HIV diagnosis 331 42 (8–101) 2044 53 (9–114) 0.084 401 68 (25–127.5) 89 89 (29.5–223) 0.022
Total bilirubin (mg/dL) 36 0.40 (0.33–0.52) 1007 0.50 (0.34–0.79) 0.101 270 1.03 (0.47–2.14) 58 0.35 (0.28–0.53) ,0.001
Plasma triglycerides (mg/dL) 27 91 (67–119) 952 90 (68–126) 0.746 239 86 (66–121) 47 93 (73–129) 0.274
Total cholesterol (mg/dL) 31 183 (155–195) 958 169 (147–194) 0.282 245 163 (143–183) 46 166 (150–190.25) 0.619
Total cholesterol/HDL
cholesterol ratio
24 3.01 (2.48–3.47) 611 3.00 (2.57–3.56) 0.497 181 3.13 (2.65–3.56) 31 3.15 (2.50–3.83) 0.760
ALT (U/L) 15 15 (8–20) 345 16 (12–22) 0.171 127 16 (12–22) 48 14.5 (11–19.75) 0.230
n % n % n % n %
Foreign nationality 337 59.1 1998 53.6 0.063 402 51.2 89 44.9 0.282
History of drug use 333 6.3 2064 6.2 0.914 407 5.9 89 4.5 0.801
HCV positive 318 13.5 1946 12.9 0.759 381 11.8 85 15.3 0.379
Diagnosis of HIV in pregnancy 331 21.5 2044 22.5 0.683 401 14.5 89 11.2 0.720
History of hypertension 328 3.0 2065 1.8 0.147 408 2.2 91 1.1 0.698
History of nephropathy 328 0.3 2060 0.9 0.254 407 1.2 91 1.1 1.000
History of diabetes 327 1.2 2057 2.1 0.273 404 3.2 91 2.2 1.000
At least one previous pregnancy 333 76.6 2064 75.6 0.694 407 78.1 91 73.6 0.353
On treatment at conception 345 62.3 2067 55.7 0.021 409 62.3 91 65.9 0.522
HBV positive 306 15.0 1954 10.5 0.019 393 11.7 87 14.9 0.405
aMann-Whitney U-test for quantitative variables; v2 or Fisher’s test for categorical variables.
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induce significant effects on lipid levels,16 most of the observed dif-
ferences were already present at the start of pregnancy and are
therefore likely to reflect general differences in the metabolic pro-
file of the two drugs and not a specific differential effect of preg-
nancy, as also suggested by the similar changes observed with the
two drugs in all laboratory parameters between first and third tri-
mesters. Finally, the differences in laboratory measures were not
accompanied by substantial differences in clinical outcomes,
including those potentially related to metabolic status, such as
maternal weight gain and prevalence of large infants by gesta-
tional age.
Overall, given the increased cardiovascular risk associated with
higher values of the total cholesterol/HDL cholesterol ratio17and
the potential association of early hypertriglyceridaemia with sub-
sequent occurrence of gestational diabetes, pre-eclampsia18,19
and fetal macrosomia,20 clinicians could consider atazanavir as a
preferable choice in particular situations where additional risk fac-
tors for the above clinical conditions are present. On the other
hand, darunavir may be preferred when hyperbilirubinaemia may
pose some concern.
The main limitation of this study, together with the sample size
considerations discussed above, is represented by the non-
randomized attribution of treatment, which does not allow us to
exclude some selection bias in prescribing. Randomized studies
are, however, difficult to perform in pregnancy and almost all
available information is based on studies with an observational
design. Overall, this study provided new comparative information
on use of atazanavir and darunavir in pregnancy, with a relatively
large sample size that included 500 cases. Overall, the main study
findings, showing no evidence of a difference in risk of adverse
pregnancy outcomes, support current recommendations. Based
on the minor differences observed in laboratory measures,
prescribing physicians might prefer either drug only in particular
situations where the expected impact of treatment on lipid profile
and bilirubin may be clinically relevant.
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Tibaldi, L. Trentini, T. Todros, G. Masuelli, V. Frisina, I. Cetin, T. Brambilla,
V. Savasi, C. Personeni, C. Giaquinto, M. Fiscon, E. Rubino, L. Franceschetti,
R. Badolato, B. Tassis, G. C. Tiso, O. Genovese, C. Cafforio, C. Pinnetti, G.
Liuzzi, A. M. Casadei, A. F. Cavaliere, M. Cellini, A. M. Marconi, S. Dalzero, V.
Sacchi, M. Ierardi, C. Polizzi, A. Mattei, M. F. Pirillo, R. Amici, C. M. Galluzzo,
S. Donnini, S. Baroncelli, M. Floridia.
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Advisory Board: A. Cerioli, M. De Martino, F. Parazzini, E. Tamburrini, S.
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Table 3. Pregnancy outcomes
Entire study populationa Atazanavir Darunavir Pb
HIV viral load ,50 copies/mL at third trimester, % 73.8 (1013/1372) 81.6 (239/293) 83.6 (56/67) 0.669
Pregnancy not ending in a live birth, %c 9.8 (114/1168) 8.3 (21/253) 15.3 (9/59) 0.103
Non-elective caesarean section, % 18.7 (326/1746) 18.6 (67/361) 18.3 (13/71) 0.961
Preterm delivery (,37 weeks), %d 19.0 (338/1780) 17.4 (63/362) 18.9 (14/74) 0.755
Very preterm delivery (,32 weeks), % 2.1 (37/1780) 1.9 (7/362) 2.7 (2/74) 0.653
Low birthweight (,2500 g), %d 20.7 (345/1666) 20.4 (70/343) 16.9 (12/71) 0.500
Very low birthweight (,1500 g), %d 2.7 (45/1666) 2.6 (9/343) 4.2 (3/71) 0.440
Small by gestational age, %e 12.7 (197/1553) 12.0 (39/326) 11.3 (8/71) 0.869
Large by gestational age, %e 6.9 (107/1553) 5.8 (19/326) 5.6 (4/71) 0.605
Complications of delivery, %f 6.4 (110/1722) 9.3 (33/353) 5.6 (4/71) 0.488
Neonatal/infant death, % 0.7 (13/1847) 1.3 (5/374) 0 0.404
Birth defects, %g 4.8 (44/921) 5.8 (12/207) 7.7 (3/39) 0.713
aAll cases followed since May 2004.
bComparison between atazanavir- and darunavir-exposed women, v2 or Fisher’s test.
cCalculated on cases exposed (on treatment) at the start of pregnancy.
dLivebirths only.
eBirthweight ,10th (small) or.90th (large) percentile by age and gender, singletons only.
fMostly represented by anaemia, fever or wound infections.
gLivebirths from mothers on treatment at the start of pregnancy.
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